INDBInternet News Database 2.5 Updated 1 min ago · 297 sources Show or hide images Light or dark

Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion

Save Like Comments Compare coverage
Image from Quartz

Summary

The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included

Description from Quartz.

Who is covering this

  1. Quartz Leans left Factuality: High US
    Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion

    The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included

Comments

Comments need JavaScript.